NeuroPace, Inc. (NASDAQ: NPCE) Stock Competitors & Peer Comparison
See NPCE's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NPCE and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NPCE | $12.77 | +4.33% | 438.3M | -22.40 | -$0.57 | N/A |
| ABT | $104.06 | -0.79% | 180.1B | 19.97 | $5.21 | +2.42% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $92.77 | -2.09% | 118.6B | 16.77 | $5.53 | +3.08% |
| SYK | $297.94 | +1.11% | 114.3B | 22.26 | $13.39 | +1.18% |
| BSX | $45.05 | +1.49% | 65.3B | 14.53 | $3.10 | N/A |
| EW | $87.22 | +0.72% | 50.3B | 32.30 | $2.70 | N/A |
| DXCM | $85.98 | -0.07% | 32.4B | 33.72 | $2.55 | N/A |
| GEHC | $69.76 | +0.27% | 31.5B | 15.30 | $4.56 | +0.20% |
| PHG | $25.50 | -0.93% | 24.9B | 14.57 | $1.75 | +3.87% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
NPCE vs ABT Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ABT has a market cap of 180.1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ABT trades at $104.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ABT's P/E ratio is 19.97. In terms of profitability, NPCE's ROE is -1.20%, compared to ABT's ROE of +0.11%. Regarding short-term risk, NPCE is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
NPCE vs BSX-PA Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NPCE's ROE is -1.20%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NPCE is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
NPCE vs MDT Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, MDT has a market cap of 118.6B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while MDT trades at $92.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas MDT's P/E ratio is 16.77. In terms of profitability, NPCE's ROE is -1.20%, compared to MDT's ROE of +0.11%. Regarding short-term risk, NPCE is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
NPCE vs SYK Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, SYK has a market cap of 114.3B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while SYK trades at $297.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas SYK's P/E ratio is 22.26. In terms of profitability, NPCE's ROE is -1.20%, compared to SYK's ROE of +0.16%. Regarding short-term risk, NPCE is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
NPCE vs BSX Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, BSX has a market cap of 65.3B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while BSX trades at $45.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas BSX's P/E ratio is 14.53. In terms of profitability, NPCE's ROE is -1.20%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NPCE is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
NPCE vs EW Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, EW has a market cap of 50.3B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while EW trades at $87.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas EW's P/E ratio is 32.30. In terms of profitability, NPCE's ROE is -1.20%, compared to EW's ROE of +0.10%. Regarding short-term risk, NPCE is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
NPCE vs DXCM Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, DXCM has a market cap of 32.4B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while DXCM trades at $85.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas DXCM's P/E ratio is 33.72. In terms of profitability, NPCE's ROE is -1.20%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, NPCE is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
NPCE vs GEHC Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, GEHC has a market cap of 31.5B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while GEHC trades at $69.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas GEHC's P/E ratio is 15.30. In terms of profitability, NPCE's ROE is -1.20%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, NPCE is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
NPCE vs PHG Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, PHG has a market cap of 24.9B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while PHG trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas PHG's P/E ratio is 14.57. In terms of profitability, NPCE's ROE is -1.20%, compared to PHG's ROE of +0.10%. Regarding short-term risk, NPCE is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
NPCE vs ZBH Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ZBH has a market cap of 18.1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ZBH trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ZBH's P/E ratio is 11.20. In terms of profitability, NPCE's ROE is -1.20%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NPCE is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
NPCE vs ABMD Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NPCE's ROE is -1.20%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NPCE is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
NPCE vs PEN Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while PEN trades at $322.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas PEN's P/E ratio is 84.20. In terms of profitability, NPCE's ROE is -1.20%, compared to PEN's ROE of +0.11%. Regarding short-term risk, NPCE is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
NPCE vs SWAV Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NPCE's ROE is -1.20%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NPCE is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
NPCE vs SNN Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, SNN has a market cap of 12.1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while SNN trades at $28.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas SNN's P/E ratio is 19.47. In terms of profitability, NPCE's ROE is -1.20%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NPCE is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
NPCE vs ALGN Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ALGN has a market cap of 10.6B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ALGN trades at $149.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ALGN's P/E ratio is 13.58. In terms of profitability, NPCE's ROE is -1.20%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, NPCE is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
NPCE vs GMED Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, GMED has a market cap of 10.2B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while GMED trades at $75.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas GMED's P/E ratio is 17.04. In terms of profitability, NPCE's ROE is -1.20%, compared to GMED's ROE of +0.12%. Regarding short-term risk, NPCE is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
NPCE vs GKOS Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, GKOS has a market cap of 9.8B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while GKOS trades at $166.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas GKOS's P/E ratio is -194.09. In terms of profitability, NPCE's ROE is -1.20%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, NPCE is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
NPCE vs PODD Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, PODD has a market cap of 9.8B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while PODD trades at $141.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas PODD's P/E ratio is 24.18. In terms of profitability, NPCE's ROE is -1.20%, compared to PODD's ROE of +0.27%. Regarding short-term risk, NPCE is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
NPCE vs BIO Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, BIO has a market cap of 9.4B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while BIO trades at $352.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas BIO's P/E ratio is 38.01. In terms of profitability, NPCE's ROE is -1.20%, compared to BIO's ROE of +0.03%. Regarding short-term risk, NPCE is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check BIO's competition here
Masimo Corporation (NASDAQ: MASI)
NPCE vs MASI Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas MASI's P/E ratio is 44.43. In terms of profitability, NPCE's ROE is -1.20%, compared to MASI's ROE of +0.09%. Regarding short-term risk, NPCE is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check MASI's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
NPCE vs BIO-B Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, BIO-B has a market cap of 9.4B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while BIO-B trades at $354.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas BIO-B's P/E ratio is -62.35. In terms of profitability, NPCE's ROE is -1.20%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, NPCE is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check BIO-B's competition here
Bruker Corporation (NASDAQ: BRKR)
NPCE vs BRKR Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, BRKR has a market cap of 8.4B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while BRKR trades at $55.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas BRKR's P/E ratio is 27.82. In terms of profitability, NPCE's ROE is -1.20%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, NPCE is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
NPCE vs BRKRP Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, BRKRP has a market cap of 8.4B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while BRKRP trades at $410.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas BRKRP's P/E ratio is 222.61. In terms of profitability, NPCE's ROE is -1.20%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, NPCE is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
NPCE vs HAE Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, HAE has a market cap of 5.4B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while HAE trades at $118.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas HAE's P/E ratio is 23.70. In terms of profitability, NPCE's ROE is -1.20%, compared to HAE's ROE of +0.11%. Regarding short-term risk, NPCE is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
NPCE vs NARI Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas NARI's P/E ratio is -59.24. In terms of profitability, NPCE's ROE is -1.20%, compared to NARI's ROE of -0.00%. Regarding short-term risk, NPCE is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
NPCE vs ITGR Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ITGR trades at $126.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ITGR's P/E ratio is 19.96. In terms of profitability, NPCE's ROE is -1.20%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, NPCE is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
NPCE vs LIVN Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while LIVN trades at $78.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas LIVN's P/E ratio is 18.56. In terms of profitability, NPCE's ROE is -1.20%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, NPCE is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
NPCE vs IRTC Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while IRTC trades at $109.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas IRTC's P/E ratio is -254.88. In terms of profitability, NPCE's ROE is -1.20%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, NPCE is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
NPCE vs NEOG Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while NEOG trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas NEOG's P/E ratio is 41.50. In terms of profitability, NPCE's ROE is -1.20%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, NPCE is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
NPCE vs TMDX Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while TMDX trades at $71.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas TMDX's P/E ratio is 36.35. In terms of profitability, NPCE's ROE is -1.20%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, NPCE is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check TMDX's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
NPCE vs UFPT Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while UFPT trades at $293.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas UFPT's P/E ratio is 29.95. In terms of profitability, NPCE's ROE is -1.20%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NPCE is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
NPCE vs NUVA Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NPCE's ROE is -1.20%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NPCE is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check NUVA's competition here
AxoGen, Inc. (NASDAQ: AXGN)
NPCE vs AXGN Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, AXGN has a market cap of 2.1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while AXGN trades at $35.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas AXGN's P/E ratio is 92.67. In terms of profitability, NPCE's ROE is -1.20%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, NPCE is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check AXGN's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
NPCE vs INSP Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, INSP has a market cap of 2B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while INSP trades at $70.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas INSP's P/E ratio is 30.89. In terms of profitability, NPCE's ROE is -1.20%, compared to INSP's ROE of +0.18%. Regarding short-term risk, NPCE is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check INSP's competition here
Butterfly Network, Inc. (NYSE: BFLY)
NPCE vs BFLY Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, BFLY has a market cap of 2B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while BFLY trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas BFLY's P/E ratio is -31.15. In terms of profitability, NPCE's ROE is -1.20%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, NPCE is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check BFLY's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
NPCE vs ESTA Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ESTA has a market cap of 1.7B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ESTA trades at $58.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ESTA's P/E ratio is -46.21. In terms of profitability, NPCE's ROE is -1.20%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, NPCE is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
NPCE vs NVCR Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, NVCR has a market cap of 1.7B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while NVCR trades at $14.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas NVCR's P/E ratio is -11.45. In terms of profitability, NPCE's ROE is -1.20%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, NPCE is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
NPCE vs ATEC Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ATEC trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ATEC's P/E ratio is -173.50. In terms of profitability, NPCE's ROE is -1.20%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, NPCE is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ATEC's competition here
Picard Medical, Inc. (AMEX: PMI)
NPCE vs PMI Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, PMI has a market cap of 1.6B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while PMI trades at $15.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas PMI's P/E ratio is -12.84. In terms of profitability, NPCE's ROE is -1.20%, compared to PMI's ROE of -9.31%. Regarding short-term risk, NPCE is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check PMI's competition here
CONMED Corporation (NYSE: CNMD)
NPCE vs CNMD Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while CNMD trades at $46.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas CNMD's P/E ratio is 10.12. In terms of profitability, NPCE's ROE is -1.20%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, NPCE is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
NPCE vs HSKA Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NPCE's ROE is -1.20%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NPCE is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check HSKA's competition here
Avanos Medical, Inc. (NYSE: AVNS)
NPCE vs AVNS Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas AVNS's P/E ratio is 27.77. In terms of profitability, NPCE's ROE is -1.20%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NPCE is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check AVNS's competition here
Enovis Corporation (NYSE: ENOV)
NPCE vs ENOV Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ENOV trades at $19.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ENOV's P/E ratio is 5.70. In terms of profitability, NPCE's ROE is -1.20%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, NPCE is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ENOV's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
NPCE vs TNDM Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while TNDM trades at $16.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas TNDM's P/E ratio is -17.61. In terms of profitability, NPCE's ROE is -1.20%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, NPCE is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check TNDM's competition here
IRadimed Corporation (NASDAQ: IRMD)
NPCE vs IRMD Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while IRMD trades at $87.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas IRMD's P/E ratio is 44.05. In terms of profitability, NPCE's ROE is -1.20%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, NPCE is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check IRMD's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
NPCE vs SILK Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas SILK's P/E ratio is -18.96. In terms of profitability, NPCE's ROE is -1.20%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NPCE is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
NPCE vs FNA Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas FNA's P/E ratio is -19.83. In terms of profitability, NPCE's ROE is -1.20%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NPCE is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check FNA's competition here
Artivion, Inc. (NYSE: AORT)
NPCE vs AORT Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while AORT trades at $22.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas AORT's P/E ratio is 37.08. In terms of profitability, NPCE's ROE is -1.20%, compared to AORT's ROE of -0.01%. Regarding short-term risk, NPCE is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check AORT's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
NPCE vs IART Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, IART has a market cap of 1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while IART trades at $13.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas IART's P/E ratio is 5.70. In terms of profitability, NPCE's ROE is -1.20%, compared to IART's ROE of -0.01%. Regarding short-term risk, NPCE is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
NPCE vs PRCT Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while PRCT trades at $18.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas PRCT's P/E ratio is -9.42. In terms of profitability, NPCE's ROE is -1.20%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, NPCE is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
NPCE vs LMRI Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, LMRI has a market cap of 1B. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while LMRI trades at $10.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas LMRI's P/E ratio is -20.86. In terms of profitability, NPCE's ROE is -1.20%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, NPCE is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check LMRI's competition here
CeriBell, Inc. (NASDAQ: CBLL)
NPCE vs CBLL Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, CBLL has a market cap of 997.8M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while CBLL trades at $26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas CBLL's P/E ratio is -14.77. In terms of profitability, NPCE's ROE is -1.20%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, NPCE is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check CBLL's competition here
Bioventus Inc. (NASDAQ: BVS)
NPCE vs BVS Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, BVS has a market cap of 921.4M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while BVS trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas BVS's P/E ratio is 17.75. In terms of profitability, NPCE's ROE is -1.20%, compared to BVS's ROE of +0.28%. Regarding short-term risk, NPCE is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check BVS's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
NPCE vs SIBN Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, SIBN has a market cap of 881.1M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while SIBN trades at $19.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas SIBN's P/E ratio is -57.82. In terms of profitability, NPCE's ROE is -1.20%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, NPCE is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check SIBN's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
NPCE vs CSII Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas CSII's P/E ratio is -20.83. In terms of profitability, NPCE's ROE is -1.20%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NPCE is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check CSII's competition here
InMode Ltd. (NASDAQ: INMD)
NPCE vs INMD Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, INMD has a market cap of 809.6M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while INMD trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas INMD's P/E ratio is 9.77. In terms of profitability, NPCE's ROE is -1.20%, compared to INMD's ROE of +0.12%. Regarding short-term risk, NPCE is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check INMD's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
NPCE vs AHCO Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, AHCO has a market cap of 801.7M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while AHCO trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas AHCO's P/E ratio is 12.00. In terms of profitability, NPCE's ROE is -1.20%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, NPCE is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check AHCO's competition here
Varex Imaging Corporation (NASDAQ: VREX)
NPCE vs VREX Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, VREX has a market cap of 781.3M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while VREX trades at $18.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas VREX's P/E ratio is 19.37. In terms of profitability, NPCE's ROE is -1.20%, compared to VREX's ROE of +0.05%. Regarding short-term risk, NPCE is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check VREX's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
NPCE vs BBNX Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, BBNX has a market cap of 757.6M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while BBNX trades at $16.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas BBNX's P/E ratio is -10.21. In terms of profitability, NPCE's ROE is -1.20%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, NPCE is more volatile compared to BBNX. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check BBNX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
NPCE vs CTKB Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, CTKB has a market cap of 682.4M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while CTKB trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas CTKB's P/E ratio is -27.81. In terms of profitability, NPCE's ROE is -1.20%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, NPCE is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
NPCE vs SRDX Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NPCE's ROE is -1.20%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, NPCE is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check SRDX's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
NPCE vs AVR Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, AVR has a market cap of 601.8M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while AVR trades at $6.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas AVR's P/E ratio is -3.18. In terms of profitability, NPCE's ROE is -1.20%, compared to AVR's ROE of -0.78%. Regarding short-term risk, NPCE is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check AVR's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
NPCE vs APEN Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas APEN's P/E ratio is -9.43. In terms of profitability, NPCE's ROE is -1.20%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NPCE is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
NPCE vs KIDS Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, KIDS has a market cap of 576.2M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while KIDS trades at $22.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas KIDS's P/E ratio is -18.70. In terms of profitability, NPCE's ROE is -1.20%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, NPCE is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check KIDS's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
NPCE vs PACB Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, PACB has a market cap of 570.4M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while PACB trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas PACB's P/E ratio is -4.48. In terms of profitability, NPCE's ROE is -1.20%, compared to PACB's ROE of -49.62%. Regarding short-term risk, NPCE is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check PACB's competition here
ZimVie Inc. (NASDAQ: ZIMV)
NPCE vs ZIMV Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NPCE's ROE is -1.20%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, NPCE is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
NPCE vs TCMD Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, TCMD has a market cap of 515.1M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while TCMD trades at $22.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas TCMD's P/E ratio is 21.06. In terms of profitability, NPCE's ROE is -1.20%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, NPCE is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check TCMD's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
NPCE vs DCTH Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, DCTH has a market cap of 498.6M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while DCTH trades at $14.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas DCTH's P/E ratio is 1437.00. In terms of profitability, NPCE's ROE is -1.20%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, NPCE is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check DCTH's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
NPCE vs SSII Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, SSII has a market cap of 491.2M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while SSII trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas SSII's P/E ratio is -40.83. In terms of profitability, NPCE's ROE is -1.20%, compared to SSII's ROE of -0.27%. Regarding short-term risk, NPCE is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check SSII's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
NPCE vs SGHT Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, SGHT has a market cap of 455M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while SGHT trades at $8.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas SGHT's P/E ratio is -14.75. In terms of profitability, NPCE's ROE is -1.20%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, NPCE is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check SGHT's competition here
Cerus Corporation (NASDAQ: CERS)
NPCE vs CERS Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, CERS has a market cap of 447.4M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while CERS trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas CERS's P/E ratio is -73.75. In terms of profitability, NPCE's ROE is -1.20%, compared to CERS's ROE of -0.10%. Regarding short-term risk, NPCE is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check CERS's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
NPCE vs SENS Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, SENS has a market cap of 424M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while SENS trades at $8.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas SENS's P/E ratio is -3.60. In terms of profitability, NPCE's ROE is -1.20%, compared to SENS's ROE of -1.66%. Regarding short-term risk, NPCE is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
NPCE vs OFIX Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, OFIX has a market cap of 387.6M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while OFIX trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas OFIX's P/E ratio is -6.25. In terms of profitability, NPCE's ROE is -1.20%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, NPCE is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
NPCE vs CV Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, CV has a market cap of 354.9M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while CV trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas CV's P/E ratio is -10.59. In terms of profitability, NPCE's ROE is -1.20%, compared to CV's ROE of -1.78%. Regarding short-term risk, NPCE is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check CV's competition here
Avita Medical Inc. (NASDAQ: RCEL)
NPCE vs RCEL Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, RCEL has a market cap of 326.4M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while RCEL trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas RCEL's P/E ratio is -9.12. In terms of profitability, NPCE's ROE is -1.20%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, NPCE is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check RCEL's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
NPCE vs SMLR Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NPCE's ROE is -1.20%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, NPCE is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check SMLR's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
NPCE vs CLPT Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, CLPT has a market cap of 279.7M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while CLPT trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas CLPT's P/E ratio is -7.77. In terms of profitability, NPCE's ROE is -1.20%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, NPCE is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check CLPT's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
NPCE vs INFU Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, INFU has a market cap of 273.9M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while INFU trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas INFU's P/E ratio is 33.54. In terms of profitability, NPCE's ROE is -1.20%, compared to INFU's ROE of +0.15%. Regarding short-term risk, NPCE is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check INFU's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
NPCE vs TMCI Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, TMCI has a market cap of 252.3M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while TMCI trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas TMCI's P/E ratio is -4.13. In terms of profitability, NPCE's ROE is -1.20%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, NPCE is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check TMCI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
NPCE vs CATX Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, CATX has a market cap of 252.3M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while CATX trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas CATX's P/E ratio is -1.66. In terms of profitability, NPCE's ROE is -1.20%, compared to CATX's ROE of -0.42%. Regarding short-term risk, NPCE is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check CATX's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
NPCE vs MGRM Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas MGRM's P/E ratio is -12.00. In terms of profitability, NPCE's ROE is -1.20%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, NPCE is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
NPCE vs ELMD Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ELMD has a market cap of 228.1M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ELMD trades at $27.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ELMD's P/E ratio is 21.02. In terms of profitability, NPCE's ROE is -1.20%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, NPCE is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
NPCE vs NVRO Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NPCE's ROE is -1.20%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NPCE is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check NVRO's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
NPCE vs TLSI Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, TLSI has a market cap of 217.4M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while TLSI trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas TLSI's P/E ratio is -2.10. In terms of profitability, NPCE's ROE is -1.20%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, NPCE is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check TLSI's competition here
Quantum-Si incorporated (NASDAQ: QSI)
NPCE vs QSI Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, QSI has a market cap of 215.9M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while QSI trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas QSI's P/E ratio is -2.36. In terms of profitability, NPCE's ROE is -1.20%, compared to QSI's ROE of -0.47%. Regarding short-term risk, NPCE is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check QSI's competition here
Profound Medical Corp. (NASDAQ: PROF)
NPCE vs PROF Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, PROF has a market cap of 214.1M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while PROF trades at $5.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas PROF's P/E ratio is -5.98. In terms of profitability, NPCE's ROE is -1.20%, compared to PROF's ROE of -0.56%. Regarding short-term risk, NPCE is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
NPCE vs RXST Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, RXST has a market cap of 195.1M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while RXST trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas RXST's P/E ratio is -4.15. In terms of profitability, NPCE's ROE is -1.20%, compared to RXST's ROE of -0.17%. Regarding short-term risk, NPCE is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
NPCE vs BSGM Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NPCE's ROE is -1.20%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, NPCE is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
NPCE vs MDGS Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NPCE's ROE is -1.20%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NPCE is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check MDGS's competition here
Inogen, Inc. (NASDAQ: INGN)
NPCE vs INGN Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, INGN has a market cap of 173.8M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while INGN trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas INGN's P/E ratio is -7.20. In terms of profitability, NPCE's ROE is -1.20%, compared to INGN's ROE of -0.13%. Regarding short-term risk, NPCE is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check INGN's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
NPCE vs QIPT Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NPCE's ROE is -1.20%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, NPCE is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
NPCE vs FOCL Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, FOCL has a market cap of 155.9M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while FOCL trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas FOCL's P/E ratio is -4.02. In terms of profitability, NPCE's ROE is -1.20%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, NPCE is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check FOCL's competition here
Neuronetics, Inc. (NASDAQ: STIM)
NPCE vs STIM Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, STIM has a market cap of 145.5M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while STIM trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas STIM's P/E ratio is -4.34. In terms of profitability, NPCE's ROE is -1.20%, compared to STIM's ROE of -1.51%. Regarding short-term risk, NPCE is more volatile compared to STIM. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check STIM's competition here
Quanterix Corporation (NASDAQ: QTRX)
NPCE vs QTRX Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, QTRX has a market cap of 131.2M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while QTRX trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas QTRX's P/E ratio is -1.09. In terms of profitability, NPCE's ROE is -1.20%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, NPCE is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for NPCE.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
NPCE vs OWLT Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, OWLT has a market cap of 121M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while OWLT trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas OWLT's P/E ratio is -29.57. In terms of profitability, NPCE's ROE is -1.20%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, NPCE is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
NPCE vs ICAD Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ICAD's P/E ratio is -20.37. In terms of profitability, NPCE's ROE is -1.20%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, NPCE is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
NPCE vs HJLI Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas HJLI's P/E ratio is N/A. In terms of profitability, NPCE's ROE is -1.20%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, NPCE is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
NPCE vs ASXC Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas ASXC's P/E ratio is -1.12. In terms of profitability, NPCE's ROE is -1.20%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, NPCE is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check ASXC's competition here
Neovasc Inc. (NASDAQ: NVCN)
NPCE vs NVCN Comparison October 2026
NeuroPace, Inc. (NASDAQ: NPCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 438.3M. In comparison, NVCN has a market cap of 82.9M. Regarding current trading prices, NPCE is priced at $12.77 on the NASDAQ, while NVCN trades at $30.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -22.40, whereas NVCN's P/E ratio is -1.99. In terms of profitability, NPCE's ROE is -1.20%, compared to NVCN's ROE of -1.21%. Regarding short-term risk, NPCE is more volatile compared to NVCN. This indicates higher risk in terms of short-term price fluctuations for NPCE.Check NVCN's competition here